<DOC>
	<DOCNO>NCT00454870</DOCNO>
	<brief_summary>The purpose study determine 8-week treatment study MEM 3454 safe effective treatment patient mild moderate Alzheimer 's disease .</brief_summary>
	<brief_title>Safety Efficacy MEM 3454 Versus Placebo Patients With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>Alzheimer 's disease lead cause dementia one common diseases age population . It chronic brain disease involve gradual memory loss , decline ability perform routine task , disorientation , difficulty learning , loss language skill , impairment judgment , personality change affect individual . The neurodegenerative nature disease eventually lead failure organ system death . A consistent marked change brain patient AD degeneration cholinergic innervation hippocampus cerebral cortex area . The activity choline acetyl transferase ( ChAT ) significantly reduce brain region , linear correlation see reduction cortical ChAT activity progress dementia , indicate progressive loss cholinergic function . Receptor selective nicotinic alpha-7 receptor agonist modulate acetylcholine selective brain region contribute symptomatic treatment AD . MEM 3454 novel nicotinic alpha-7 receptor selective partial agonist serotonin type 3 ( 5-HT3 ) receptor antagonist property .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis probable possible Alzheimer 's disease MMSE score 16 26 point Modified Hachinski Ischemia Score less equal 4 Capable perform cognitive test procedure specify protocol Head trauma associate cognitive impairment Evidence significant neurological disease AD , Parkinson 's disease , multiinfarct dementia , Huntington 's disease , normal pressure hydrocephalus , CNS tumor , progressive supranuclear palsy , seizure disorder , etc . Received AChE inhibitor therapy ( e.g. , rivastigmine , tacrine galantamine ) NDMAreceptor antagonist , memantine , within 30 day donepezil within 40 day randomization Received investigational drug within 2 month randomization treatment nicotinic receptor agonist within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Cognition</keyword>
	<keyword>Cognitive impairment</keyword>
</DOC>